Comparing the cost-effectiveness of SGLT2i versus mineralocorticoid antagonists

FHS
June 19, 2023
2:43 pm

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are approved for heart failure with reduced ejection fraction (HFrEF).

An Arm and a Leg: The hack

When Change Healthcare, a subsidiary of UnitedHealth Group, got hit by a cyberattack this winter, a big chunk of the nation’s doctors, pharmacists, hospitals, and

April 30, 2024

Can your diet soda habit affect your baby? New study explores low-calorie sweeteners in breastmilk

U.S. scientists are studying if low-calorie sweeteners like sucralose and acesulfame-potassium can be transferred from mothers to infants through breastfeeding. This first-of-its-kind pharmacokinetic model aims

October 26, 2023

Bluebird snags more outcomes-based coverage for its $3M+ sickle cell gene therapy

A second outcomes-based agreement with an unidentified payer is now in the books for bluebird bio’s new $3.1 million sickle cell gene therapy, the company

January 5, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.